Medication & Safety
How Much Does Ozempic Cost? A Country-by-Country Guide
Ozempic costs $800–$1000 per month in the US without insurance. Costs vary widely globally. Here is the complete breakdo...
Ozempic and Wegovy contain the same molecule: semaglutide. The difference is the approved dose, the intended use, and the regulatory indication. For weight loss, Wegovy is the approved version. For type 2 diabetes, Ozempic is the approved version. In clinical practice, many physicians use Ozempic at Wegovy-equivalent doses for weight loss because the two drugs are pharmacologically identical.
This question is one of the most searched in weight loss medicine because the distinction sounds important but is largely administrative rather than medical.
The Same Molecule
Novo Nordisk produces both drugs. Semaglutide is synthesised identically for both products. The active ingredient in a 2 mg Ozempic dose and in a 2 mg Wegovy dose is the same semaglutide molecule at the same purity.
Think of it this way: if two pharmacies fill the same semaglutide molecule into different-labelled pens, the biological effect is identical. That is essentially what Ozempic and Wegovy are.
The Dose Difference
This is the one clinically meaningful distinction. Ozempic is approved at maximum doses of 0.5 mg, 1 mg, and 2 mg weekly for diabetes management. Wegovy escalates to a maximum of 2.4 mg weekly.
The STEP 1 trial that established semaglutide's weight loss credentials used the 2.4 mg Wegovy dose. At this dose, average weight loss was 14.9% of body weight. At Ozempic's 1 mg dose, average weight loss in comparable studies is around 6 to 8%.
Physicians who prescribe Ozempic off-label for weight loss often target 2 mg or 2.4 mg — effectively using it as Wegovy. The drug allows this. The only difference is the label on the pen.
The Approval Difference
Ozempic is approved for: reducing cardiovascular events in type 2 diabetics with established heart disease, and improving glycaemic control in type 2 diabetes.
Wegovy is approved for: chronic weight management in adults with BMI over 30 (obesity) or BMI over 27 with a weight-related condition (overweight with comorbidity).
In countries where insurance covers prescription drugs, this distinction matters enormously — coverage for Wegovy (obesity) is different from coverage for Ozempic (diabetes). In Pakistan, neither is officially registered, so the distinction is less relevant.
Cost Differences
In markets where both are available, Wegovy is typically priced higher than Ozempic. This created a well-documented substitution: patients prescribed Wegovy for weight loss often use Ozempic at the same dose because it is more available and less expensive.
Which Should You Use?
If your goal is weight loss and you live in a market where both are available: either. At equivalent doses, results are equivalent. The practical choice is availability and cost.
If you have type 2 diabetes: Ozempic's approval for diabetes management is what your insurer and your physician will reference.
If you live in Pakistan: METASLIM is the only DRAP-registered GLP-1 support option currently available. It targets the same GLP-1 receptor pathway as both Ozempic and Wegovy through sublingual drops, without injection and without import risk.